Pathology and Lab Medicine

Episodes 1-16 of 24

• 

  RestartResume

  HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)

  RestartResume

  HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)

  Project Oncology®

  HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)

  • 

    

    Fernando López-Ríos, MD, PhD

  • 

    

    Christian Rolfo, MD, PhD

  • 

    

    Charlie Gourley, MD, PhD

• 

  RestartResume

  Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma

  RestartResume

  Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma

  MinuteCE®

  Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma

  1.25 program credits

  • 

    

    Ignacio Duran, MD

  • 

    

    Wenxin Xu, MD

  1.25 program credits

• 

  RestartResume

  Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma

  RestartResume

  Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma

  MinuteCE®

  Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma

  1.25 program credits

  • 

    

    Ignacio Duran, MD

  • 

    

    Sandy Srinivas, MD

  1.25 program credits

• 

  RestartResume

  Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies

  RestartResume

  Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies

  MinuteCE®

  Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies

  1.25 program credits

  • 

    

    Ignacio Duran, MD

  • 

    

    Wenxin Xu, MD

  1.25 program credits

• 

  RestartResume

  Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy

  RestartResume

  Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy

  MinuteCE®

  Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy

  1.25 program credits

  • 

    

    Wenxin Xu, MD

  • 

    

    Sandy Srinivas, MD

  1.25 program credits

• 

  MinuteCE®

  Innovations in Oncology Learning Center From Guidelines to Practice: Genitourinary Cancers

  1.25 credits 10 episodes

  • 

    

    Ignacio Duran, MD

  • 

    

    Wenxin Xu, MD

  • 

    

    Sandy Srinivas, MD

  1.25 credits 10 episodes

• 

  RestartResume

  Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer

  RestartResume

  Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer

  MinuteCE®

  Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer

  1.25 program credits

  • 

    

    Ignacio Duran, MD

  • 

    

    Sandy Srinivas, MD

  1.25 program credits

• 

  RestartResume

  Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma

  RestartResume

  Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma

  MinuteCE®

  Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma

  1.25 program credits

  • 

    

    Wenxin Xu, MD

  • 

    

    Sandy Srinivas, MD

  1.25 program credits

• 

  RestartResume

  Emerging targeted therapy combination strategies in genitourinary malignancies

  RestartResume

  Emerging targeted therapy combination strategies in genitourinary malignancies

  MinuteCE®

  Emerging targeted therapy combination strategies in genitourinary malignancies

  1.25 program credits

  • 

    

    Ignacio Duran, MD

  1.25 program credits

• 

  RestartResume

  Emerging immunotherapy combination strategies in genitourinary malignancies

  RestartResume

  Emerging immunotherapy combination strategies in genitourinary malignancies

  MinuteCE®

  Emerging immunotherapy combination strategies in genitourinary malignancies

  1.25 program credits

  • 

    

    Sandy Srinivas, MD

  1.25 program credits

• 

  RestartResume

  Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer

  RestartResume

  Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer

  MinuteCE®

  Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer

  1.25 program credits

  • 

    

    Wenxin Xu, MD

  • 

    

    Sandy Srinivas, MD

  1.25 program credits

• 

  RestartResume

  Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer

  RestartResume

  Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer

  MinuteCE®

  Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer

  1.25 program credits

  • 

    

    Ignacio Duran, MD

  • 

    

    Wenxin Xu, MD

  1.25 program credits

• 

  RestartResume

  Interprofessional Coordination of Adverse Event Management

  RestartResume

  Interprofessional Coordination of Adverse Event Management

  MinuteCE®

  Interprofessional Coordination of Adverse Event Management

  1.25 program credits

  • 

    

    Nadia Harbeck, MD, PhD

  1.25 program credits

• 

  RestartResume

  Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice

  RestartResume

  Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice

  MinuteCE®

  Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice

  1.25 program credits

  • 

    

    Hope S. Rugo, MD, FASCO

  • 

    

    Nadia Harbeck, MD, PhD

  1.25 program credits

• 

  MinuteCE®

  Precision Timing: Unveiling the Impact of CDK4/6 Inhibition in Early HR+/HER2- Breast Cancer

  1.25 credits 10 episodes

  • 

    

    Hope S. Rugo, MD, FASCO

  • 

    

    Nadia Harbeck, MD, PhD

  1.25 credits 10 episodes

• 

  RestartResume

  Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor

  RestartResume

  Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor

  MinuteCE®

  Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor

  1.25 program credits

  • 

    

    Hope S. Rugo, MD, FASCO

  • 

    

    Nadia Harbeck, MD, PhD

  1.25 program credits

• Prev
• 1
• 2
• Next